Evidence map›Paper›PMID 40397119›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

Anti-osteoporotic effect of sitagliptin in an osteoporosis model of ovariectomized rats: role of RUNX2 and RANKL/OPG ratio.

Salma Ahmed El-Marasy, Rehab F Abdel-Rahman, Reham M Abd-Elsalam, Hanan A Ogaly, Rasha M Allam

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Salma Ahmed El-MarasyDepartment of Pharmacology, Medical Research and Clinical Studies Institute, National Research Centre, Giza, Egypt. salma_el_marasy@hotmail.com.
Rehab F Abdel-RahmanDepartment of Pharmacology, Medical Research and Clinical Studies Institute, National Research Centre, Giza, Egypt.
Reham M Abd-ElsalamDepartment of Pathology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt.
Hanan A OgalyDepartment of Biochemistry and Chemistry of Nutrition, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt.
Rasha M AllamDepartment of Pharmacology, Medical Research and Clinical Studies Institute, National Research Centre, Giza, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study examines the potential anti-osteoporotic effect of sitagliptin in osteoporosis instigated by ovariectomy (OVX) in rats. Rats were assigned into 4 groups: Sham-operated, OVX group, and OVX rats orally treated with sitagliptin (10, 20 mg/kg), respectively, after 8 weeks of OVX for 4 weeks. Biochemical, real-time polymerase chain reaction, histopathological, and immunohistochemical analyses of bone resorption and formation were conducted. Sitagliptin ameliorated bone mineral density (BMD), restored calcium and phosphorus levels in OVX rats, elevated catalase and decreased malondialdehyde, reduced receptor activator of NF-κB ligand (RANKL), elevated osteoprotegerin (OPG), and reduced tartrate-resistant acid phosphatase (TRAP) femur contents. Sitagliptin mitigated variations in mRNA expressions of RUNX2 and protein kinase B (AKT) in femur tissue. Moreover, sitagliptin reduced caspase-3 protein expression and improved bone histomorphology and mechanical properties. Sitagliptin's anti-oxidant activity mediated its anti-osteoporotic effect in OVX rats via modulation of RUNX2, downregulation of RANKL/OPG, AKT pathways, apoptosis, and histomorphometry alterations revealing attenuation of osteoclastogenesis and promotion of osteoblast formation.

Indexed as

Bone Density Conservation AgentsCore Binding Factor Alpha 1 SubunitOsteoporosisOsteoprotegerinRANK LigandSitagliptin PhosphateAnimalsBone DensityDisease Models, AnimalFemaleFemurOvariectomyProto-Oncogene Proteins c-aktRatsRats, Sprague-DawleyBone Density Conservation AgentsCore Binding Factor Alpha 1 SubunitOsteoprotegerinProto-Oncogene Proteins c-aktRANK LigandRunx2 protein, ratSitagliptin PhosphateTnfrsf11b protein, ratOvariectomyRANKL/OPGRatsRUNX2SitagliptinTRAP

Identifiers

PMID40397119
PMCPMC12552293

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.